Expertise in
2
conditions

Masahiro Takada

Osaka, JP 
Expertise in
2
conditions
Osaka, JP 

Overview

Masahiro Takada practices practicing medicine in Osaka, Japan.

Mr. Takada is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, Cerebral Hypoxia, and Pustules.

He is actively involved in clinical research, co-authoring 51 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Osaka, Japan
Other Locations
Hirakata, 5731191, Japan
Kyoto, Japan
Nagoya, 4668550, Japan
Kawahara, 6068507, Japan
Tokyo, Japan
Kashiwa, 2778583, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy Plus Palbociclib Versus Hormonal Therapy Plus Placebo in Women With Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy Plus Palbociclib Versus Hormonal Therapy Plus Placebo in Women With Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
Enrollment Status: Completed
Publish Date: March 10, 2023
Intervention Type: Drug
Study Drugs: Palbociclib, Endocrine Therapy
Study Phase: Phase 3
Phase Ib/II Study to Assess Efficacy, Safety & Immunological Biomarker of Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer
Phase Ib/II Study to Assess Efficacy, Safety & Immunological Biomarker of Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: January 19, 2023
Intervention Type: Drug
Study Drug: Anti PD-1 Antibody
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

51 Total Publications

Early-Onset Direct Antiglobulin Test-Negative Autoimmune Hemolytic Anemia Induced by Pembrolizumab in Perioperative Triple-Negative Breast Cancer: A Case Report.
Early-Onset Direct Antiglobulin Test-Negative Autoimmune Hemolytic Anemia Induced by Pembrolizumab in Perioperative Triple-Negative Breast Cancer: A Case Report.
Journal: Case reports in oncology
Published: March 13, 2026

Frequently Asked Questions about Masahiro Takada

Is Masahiro Takada a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Masahiro Takada is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Masahiro Takada participate in research or clinical trials?

Yes. Masahiro Takada has published 51 articles and abstracts on conditions like Breast Cancer. You can view a list of Masahiro Takada's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Takada's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile